Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody
Friday, December 22, 2006 1 min read
Key Takeaway: Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody
Full Press Release Details
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth Blocking Delta-like Ligand 4 May Benefit Patients with Tumors Resistant to Other Anti-Angiogenesis Therapies Regeneron’s VelocImmune Technology Used to Create Fully Human Antibody.